Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Highlights,Financial firms have revised their evaluations of Regeneron Pharmaceuticals.,The company reported strong earnings ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. As of January 28, 2025 ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Market Perform to Outperform. There are 2,472 funds or institutions ...